换一批
换一批An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab (Retraction of Vol 13, Pg S 410, 2019)
作者：
发布时间
2021-02-10
- 浏览0
Journal of Crohn’s & colitis
428-428页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
